← Back to Patent Explorer
US4650787A Expired / Lapsed US ⏱️ 0.0 years remaining

Biologically active octapeptides

Assignee: Tulane University
•
Filing: 1985-04-25
•
Granted: 1987-03-17
•
Expires: 2005-04-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Novel compositions of the formula ##STR1## wherein A represents an L, D or DL amino-acid selected from the group consisting of Ala, Val, Phe, p-Cl-Phe, Trp, Pro, Ser, Thr, Glu, Gly, Beta Ala, Abu, N-Me Ala, 5-F-Trp, 5-Br-Trp, 5-Cl-Trp, their acetylated derivatives or a pharmaceutically acceptable acid addition salt thereof; B represents an L, D or DL amino acid amide selected from the group consisting of Thr NH 2 , Val NH 2 , Pro NH 2 , HO-Pro NH 2 , Ser NH 2 , Tyr NH 2 , Trp NH 2 , 5-F-Trp NH 2 , For-Trp NH 2 , Ala NH 2 , Gly NH 2 , Me Ala NH 2 ; X represents L-Phe or L-Tyr, Y represents L-Thr or L-Val; Z is L, D or DL-5-F-Trp, 5-Br-Trp, 5-Cl-Trp, 5-I-Trp or D-Trp; and C" and C' represent L or D Cys, Abu, Asp or Lys; and the pharmaceutically acceptable acid addition salts thereof; are useful as agents for inhibiting the release of growth hormone, for the treatment of gastrointestinal disorders and for therapy of certain cancers and the management of diabetes. These biologically active octapeptides all possess a terminal amino acid amide at position 8 and are prepared by solid phase methods.

Inventors

  • 👤 Andrew V. Schally
  • 👤 Ren Z. Cai

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 17:06
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/655; C07K14/6555; A; A61; A61P; A61P5/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/16

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 160 words
A compound of the formula ##STR39## wherein A is an L, D or DL amino acid selected from the group consisting of phenylalanine (Phe), its acetylated derivatives or a pharmaceutically acceptable acid addition salt thereof; B is an L, D or DL amino acid selected from the group consisting of threonine amid (Thr NH 2 ), tyrosine amide (Tyr NH 2 ), tryptophan amide (Trp NH 2 ); X is L-phenylalanine (L-Phe) or L-tyrosine (L-Tyr); Y is L-valine (L-Val); Z is D-tryptophan (D-Trp); and C" and C' are L or D-cysteine (Cys), -aminobutyric acid (Abu), aspartic acid (Asp) or lysine (Lys); provided that where C' is Cys, C" is also Cys and where C' or C" are other than Cys, C" is different from C' and is other than Cys; the connecting line between C" and C' signifies a bridge selected from the group consisting of carbon/carbon, carbon/sulfur, sulfur/sulfur and amide bridges; and the pharmaceutically acceptable acid addition salts thereof.
Claim 2
Dependent Claim 160 words
A compound of the formula ##STR39## wherein A is an L, D or DL amino acid selected from the group consisting of phenylalanine (Phe), its acetylated derivatives or a pharmaceutically acceptable acid addition salt thereof; B is an L, D or DL amino acid selected from the group consisting of threonine amid (Thr NH 2 ), tyrosine amide (Tyr NH 2 ), tryptophan amide (Trp NH 2 ); X is L-phenylalanine (L-Phe) or L-tyrosine (L-Tyr); Y is L-valine (L-Val); Z is D-tryptophan (D-Trp); and C" and C' are L or D-cysteine (Cys), -aminobutyric acid (Abu), aspartic acid (Asp) or lysine (Lys); provided that where C' is Cys, C" is also Cys and where C' or C" are other than Cys, C" is different from C' and is other than Cys; the connecting line between C" and C' signifies a bridge selected from the group consisting of carbon/carbon, carbon/sulfur, sulfur/sulfur and amide bridges; and the pharmaceutically acceptable acid addition salts thereof.
Claim 3
Dependent Claim 23 words
An octapeptide (reduced form) of the formula A-C"-X-Z-Lys-Y-C'-B wherein A, C", X, Z, Y, C' and B are as defined in claim 1.
Claim 4
Dependent Claim 23 words
A compound according to claim 1 wherein C" is Cys; X is Tyr; Z is D-Trp; Y is Val; and C' is Cys.
Claim 5
Dependent Claim 20 words
A compound according to claim 1 wherein C" is Cys; X is Tyr; Y is Val; and C' is Cys.
Claim 6
Dependent Claim 9 words
A compound according to claim 1 which is ##STR40##
Claim 7
Dependent Claim 9 words
A compound according to claim 1 which is ##STR41##
Claim 8
Dependent Claim 9 words
A compound according to claim 1 which is ##STR42##
Claim 9
Dependent Claim 9 words
A compound according to claim 1 which is ##STR43##
Claim 10
Dependent Claim 24 words
An octapeptide (reduced form) of the formula A-C"-X-Z-Lys-Y-C'-B (I') wherein A, C", X, Z, Y, C' and B are as defined in claim 1.
Claim 11
Dependent Claim 11 words
A compound according to claim 2 which is: D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 .
Claim 12
Dependent Claim 11 words
A compound according to claim 9 which is: D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Ser-NH 2 .
Claim 13
Dependent Claim 9 words
A compound according to claim 9 which is: ##STR44##
Claim 14
Dependent Claim 11 words
A compound according to claim 12 which is: D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Tyr-NH 2 .
Claim 15
Dependent Claim 37 words
A pharmaceutical composition effective for reducing growth hormone serum levels which comprises an octapeptide of claim 1, its reduced form or a pharmaceutically acceptable acid addition salt thereof in a pharmaceutically acceptable liquid or solid carrier thereof.
Claim 16
Dependent Claim 12 words
A pharmaceutical composition of claim 14 which is encapsulated in poly(d,l-lactide-co-glycolide) microcapsules.
Claim 17
Dependent Claim 46 words
A method of treating excess release of growth hormone, gastrointestinal disorders, and diabetes in a mammal in need of such therapy which comprises administering to said mammal an effective dose of octapeptide of claim 1, its reduced form, or a pharmaceutically acceptable acid addition salt thereof.

References Cited (Backward Citations)

US4209426A Cited
US4395403A Cited
EP0030920A2 Cited
US4282143A Cited
US4435385A Cited
US4443434A Cited
GB2125799A Cited
US4496543A Cited
US4451394A Cited
US4440904A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-03-16 1990-09-15 1991-03-17 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-03-16 1994-09-15 1995-03-17 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-03-16 1998-09-15 1999-03-17 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag